# AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics

> **NCT05281601** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 46 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **DRUG:** AZD7442

## Key facts

- **NCT ID:** NCT05281601
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-21
- **Primary completion:** 2024-04-16
- **Final completion:** 2024-04-16
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05281601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05281601, "AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05281601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*